Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Elevation of serum lipid peroxide level associated with doxorubicin toxicity and its amelioration by [dl]-α-tocopheryl acetate or coenzyme Q10 in mouse (doxorubicin, toxicity, lipid peroxide, tocopherol, coenzyme Q10)

  • 36 Accesses

  • 22 Citations

Summary

Elevations of serum lipid peroxide levels were demonstrated in mice after an equitoxic dose of doxorubicin. When BDF1 mice were injected with doxorubicin (20 mg/kg body weight, IP), lipid peroxide levels in sera were elevated 1 day after the injection and the levels declined on subsequent days. 5-Fluorouracil (400 mg/kg body weight, IP) never changed the peroxide levels in serum. Furthermore, it was found that the co-administration of [dl]-α-tocopheryl acetate or coenzyme Q10 IM strongly inhibited the doxorubicin-induced elevation of lipid peroxides in serum.

The effectiveness of [dl]α-tocopheryl acetate or coenzyme Q10 in reducing the lethality of doxorubicin in mice was also confirmed.

These results indicate that the measurement of serum 2-thiobarbituric acid-reacting substances provides a useful measurement of lipid peroxide levels, a useful measurement of lipid peroxide levels, which may be involved in some way with doxorubicin toxicity, and that the administration of antioxidants provide protection against some of the side effects of doxorubicin.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Bertazzoli, C., Ghione, M.: Adriamycin-associated cardiotoxicity: Research on prevention with coenzyme Q. Pharmacol. Res. Commun. 9, 235–250 (1977)

  2. 2.

    Blum, R. H., Carter, S. K.: Adriamycin — A new anticancer drug with significant clinical activity. Ann. Intern. Med. 80, 249–259 (1974)

  3. 3.

    Bonadonna, G., Monfardini, S., de Lena, M., Fossati-Bellani, F., Beretta, G.: Phase I and preliminary phase II evaluation of adriamycin (NSC-123127). Cancer Res. 30, 2572–2582 (1970)

  4. 4.

    Carter, S. K.: Adriamycin — A review. J. Natl. Cancer Inst. 55, 1265–1274 (1975)

  5. 5.

    DiMarco, A., Gaetoni, M., Scarpinato, B.: Adriamycin (NSC-123127): A new antibiotic with antitumor activity. Cancer Chemother. Rep. 53, 33–37 (1969)

  6. 6.

    Gallo-Torres, H. E.: Obligatory role of bile for the intestinal absorption of vitamin E. Lipids 5, 379–384 (1970)

  7. 7.

    Goodman, J., Hochstein, P.: Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin. Biochem. Biophys. Res. Commun. 77, 797–803 (1977)

  8. 8.

    Handa, K., Sato, S.: Generation of free radicals of quinone group-containing anticancer chemicals in NADPH-microsome system, as evidenced by initiation of sulfite oxidation. Gann 66, 43–47 (1975)

  9. 9.

    Iwamoto, Y., Hansen, I. L., Porter, T. H., Folkers, K.: Inhibition of coenzyme Q10-enzymes, succinoxidase and NADH-oxidase, by adriamycin and other quinones having antitumor activity. Biochem. Biophys. Res. Commun. 58, 633–638 (1974)

  10. 10.

    Jaenke, R. S.:An anthracycline antibiotic-induced cardiomyopathy in rabbits. Lab. Invest. 30, 292–304 (1974)

  11. 11.

    Lefpak, E. A., Pitha, J., Rosenheim, S., Gottlieb, J. A.: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32, 302–314 (1974)

  12. 12.

    Lenaz, L., Page, J. A.: Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat. Rev. 3, 111–120 (1976)

  13. 13.

    Mettler, F. P., Young, D. M., Ward, J. M.: Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res. 37, 2705–2713 (1977)

  14. 14.

    Myers, C. E., McGuire, W. P., Liss, R. H., Ifrim, I., Grotzinger, K., Young, R. C.: Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197, 165–167 (1977)

  15. 15.

    Myers, C. E., McGuire, W. P., Young, R.: Adriamycin: Amelioration of toxicity by α-tocopherol. Cancer Treat. Rep. 60, 961–962 (1976)

  16. 16.

    Oki, T., Matsuzawa, Y., Yoshimoto, A., Numata, K., Kitamura, I., Hori, S., Takamatsu, A., Umezawa, H., Ishizuka, M., Naganawa, H., Suda, H., Hamada, M., Takeuchi, T.: New antibiotics, aclacinomycin A and B. J. Antibiot. (Tokyo) 28, 830–834 (1975)

  17. 17.

    rosenoff, S. H., Brooks, E., Bostick, f., Young, R. C.: Alteration in DNA synthesis in cardiac tissue induced by adriamycin in vivo-relation to fatal toxicity. Biochem. Pharmacol. 24, 1898–1901 (1971)

  18. 18.

    Rosenoff, S. H., Olson, H. M., Young, D. M., Bostick, F., Young, R. C.: Adriamycin-induced cardiac damage in the mouse: A small-animal model of cardiotoxicity. J. Natl. Cancer Inst. 55, 191–194 (1975)

  19. 19.

    Slater, T. F.: Free radical mechanisms in tissue injury, pp. 49–61. London: Pion 1972

  20. 20.

    Yagi, K.: A simple fluorometric assay for lipoperoxide in blood plasma. Biochem. Med. 15, 212–216 (1976)

  21. 21.

    Yamanaka, N., Kato, T., Nishida, K., Ota, K.: Enhancement of DNA chain breakage by bleomycin A2 in the presence of microsomes and reduced nicotinamide adenine dinucleotide phosphate. Cancer Res. 38, 3900–3903 (1978)

  22. 22.

    Young, D. M.: Pathologic effects of adriamycin (NSC-123127) in experimental systems. Cancer Chemother. Rep. 6, 159–175 (1975)

Download references

Author information

Correspondence to Naoki Yamanaka.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yamanaka, N., Kato, T., Nishida, K. et al. Elevation of serum lipid peroxide level associated with doxorubicin toxicity and its amelioration by [dl]-α-tocopheryl acetate or coenzyme Q10 in mouse (doxorubicin, toxicity, lipid peroxide, tocopherol, coenzyme Q10). Cancer Chemother. Pharmacol. 3, 223–227 (1979). https://doi.org/10.1007/BF00254735

Download citation

Keywords

  • Lipid
  • Body Weight
  • Peroxide
  • Lipid Peroxide
  • Cancer Research